Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirapazamine with Chemoradiotherapy for Limited Stage Small Cell Lung Cancer
NCT00066742Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2003
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tirapazamine in small cell lung cancer (SCLC), sponsored by National Cancer Institute. Primary endpoint: Overall Survival at 3 years. Started Sep 2003; status: completed.
02
Drugs
tirapazamine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00066742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00066742.